CCCC

Company Overview — What Does C4 Therapeutics, Inc. Do?

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. C4 Therapeutics, Inc. (CCCC) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Andrew J. Hirsch and employs approximately 150 people. With a market capitalization of $263M, CCCC is one of the notable companies in the Healthcare sector.

C4 Therapeutics, Inc. (CCCC) Stock Rating — Reduce (April 2026)

As of April 2026, C4 Therapeutics, Inc. receives a Reduce rating with a composite score of 35.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.CCCC ranks #2,050 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, C4 Therapeutics, Inc. ranks #227 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

CCCC Stock Price and 52-Week Range

C4 Therapeutics, Inc. (CCCC) currently trades at $2.60. The stock lost $0.23 (8.3%) in the most recent trading session. The 52-week high for CCCC is $3.65, which means the stock is currently trading -28.9% from its annual peak. The 52-week low is $1.08, putting the stock 139.2% above its annual trough. Recent trading volume was 2.7M shares, reflecting moderate market activity.

Is CCCC Overvalued or Undervalued? — Valuation Analysis

C4 Therapeutics, Inc. (CCCC) carries a value factor score of 15/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.04x, versus the sector average of 2.75x. The price-to-sales ratio is 6.64x, compared to 1.66x for the average Healthcare stock.

At current multiples, C4 Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

C4 Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

C4 Therapeutics, Inc. (CCCC) earns a quality factor score of 24/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -42.5%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -30.4% versus the sector average of -33.1%.

On a margin basis, C4 Therapeutics, Inc. reports gross margins of 100.0%, compared to 71.5% for the sector. The operating margin is -333.6% (sector: -66.1%). Net profit margin stands at -303.3%, versus -58.7% for the average Healthcare stock. Revenue growth is running at -6.5% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

CCCC Debt, Balance Sheet, and Financial Health

C4 Therapeutics, Inc. has a debt-to-equity ratio of 40.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 7.81x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $59M.

CCCC has a beta of 1.50, meaning it is more volatile than the broader market — a $10,000 investment in CCCC would be expected to move 49.7% more than the S&P 500 on any given day. The stability factor score for C4 Therapeutics, Inc. is 23/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

C4 Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, C4 Therapeutics, Inc. reported revenue of $40M and earnings per share (EPS) of $-1.27. Net income for the quarter was $-109M. Gross margin was 100.0%. Operating income came in at $-120M.

In FY 2025, C4 Therapeutics, Inc. reported revenue of $36M and earnings per share (EPS) of $-1.27. Net income for the quarter was $-105M. Revenue grew 1.0% year-over-year compared to FY 2024. Operating income came in at $-115M.

In Q3 2025, C4 Therapeutics, Inc. reported revenue of $11M and earnings per share (EPS) of $-0.44. Net income for the quarter was $-32M. Revenue grew -26.9% year-over-year compared to Q3 2024. Operating income came in at $-34M.

In Q2 2025, C4 Therapeutics, Inc. reported revenue of $6M and earnings per share (EPS) of $-0.37. Net income for the quarter was $-26M. Revenue grew -46.2% year-over-year compared to Q2 2024. Operating income came in at $-29M.

Over the past 8 quarters, C4 Therapeutics, Inc. has demonstrated a growth trajectory, with revenue expanding from $12M to $40M. Investors analyzing CCCC stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

CCCC Dividend Yield and Income Analysis

C4 Therapeutics, Inc. (CCCC) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

CCCC Momentum and Technical Analysis Profile

C4 Therapeutics, Inc. (CCCC) has a momentum factor score of 61/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 35/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 48/100 reflects moderate short selling activity.

CCCC vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, C4 Therapeutics, Inc. (CCCC) ranks #227 out of 838 stocks based on the Blank Capital composite score. This places CCCC in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing CCCC against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full CCCC vs S&P 500 (SPY) comparison to assess how C4 Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

CCCC Next Earnings Date

No upcoming earnings date has been announced for C4 Therapeutics, Inc. (CCCC) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy CCCC? — Investment Thesis Summary

The quantitative profile for C4 Therapeutics, Inc. suggests caution. The quality score of 24/100 flags below-average profitability. The value score of 15/100 indicates premium valuation. Price momentum is positive at 61/100, suggesting the trend favors buyers. High volatility (stability score 23/100) increases portfolio risk.

In summary, C4 Therapeutics, Inc. (CCCC) earns a Reduce rating with a composite score of 35.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on CCCC stock.

Related Resources for CCCC Investors

Explore more research and tools: CCCC vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare CCCC head-to-head with peers: CCCC vs AZN, CCCC vs SLGL, CCCC vs VMD.